Data Year:

For its 2024 fiscal year, NOVAVAX INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
John J. Trizzino
President and Chief Operating Officer
Total Compensation $1,633,417 View details Pay Rank By Title In Biotechnology industry #100 View more
James P. Kelly
EVP, Chief Financial Officer and Treasurer
Total Compensation $1,829,489 View details Pay Rank By Title In Biotechnology industry #253 View more
John C. Jacobs
President and CEO
Total Compensation $5,087,461 View details Pay Rank By Title In Biotechnology industry #256 View more
Filip Dubovsky M.D.
Former President, Research & Development
Total Compensation $1,554,368 View details Pay Rank By Title In Biotechnology industry #51 View more
Mark J. Casey
EVP, Chief Legal Officer and Corporate Secretary
Total Compensation $1,062,334 View details Pay Rank By Title In Biotechnology industry #81 View more
Elaine O'Hara
EVP, Chief Strategy Officer
Total Compensation $1,638,116 View details Pay Rank By Title In Biotechnology industry #129 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at NOVAVAX INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. NOVAVAX INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. NOVAVAX INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
John J. Trizzino
President and Chief Operating Officer
Total Cash $844,736 Equity $776,160 Other $12,521 $1,633,417
James P. Kelly
EVP, Chief Financial Officer and Treasurer
Total Cash $867,129 Equity $948,640 Other $13,720 $1,829,489
John C. Jacobs
President and CEO
Total Cash $1,436,811 Equity $3,536,850 Other $113,800 $5,087,461
Filip Dubovsky M.D.
Former President, Research & Development
Total Cash $586,254 Equity $776,160 Other $191,954 $1,554,368
Mark J. Casey
EVP, Chief Legal Officer and Corporate Secretary
Total Cash $877,812 Equity $64,680 Other $119,842 $1,062,334
Elaine O'Hara
EVP, Chief Strategy Officer
Total Cash $893,763 Equity $646,800 Other $97,553 $1,638,116
For its 2024 fiscal year, NOVAVAX INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
John C. Jacobs CEO Pay $5,087,461 Median Employee Pay $161,162 CEO Pay Ratio 32:1
For its 2024 fiscal year, NOVAVAX INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
David Mott Total Cash $468,614
Gregg H. Alton, J.D. Total Cash $453,427
James F. Young, Ph.D. Total Cash $515,328
Margaret G. McGlynn, R. Ph. Total Cash $466,082
Rachel K. King Total Cash $456,114
Richard H. Douglas, Ph.D. Total Cash $470,614
Richard J. Rodgers Total Cash $476,427
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.